Precision interventional chemotherapy helps a Polish patient overcome late-stage metastatic cancer!

Ms. M (pseudonym) , a 36-year-old woman from Poland , was a primary cervical cancer patient. After receiving conventional treatment in her hometown , she experienced frequent discomfort, and examinations suggested suspected multiple metastases—meaning her disease had progressed to an advanced stage, with little prospect of recovery under conventional treatment. Unwilling to give up, she traveled to Beijing with the assistance of Harbor Health, seeking help from Peking University Cancer Hospital.

Case Overview

Ms. M (pseudonym) , a 36-year-old woman from Poland , was a primary cervical cancer patient. After receiving conventional treatment in her hometown , she experienced frequent discomfort, and examinations suggested suspected multiple metastases—meaning her disease had progressed to an advanced stage, with little prospect of recovery under conventional treatment. Unwilling to give up, she traveled to Beijing with the assistance of Harbor Health, seeking help from Peking University Cancer Hospital.

Cause & Challenge

Harbor Health quickly assisted Ms. M in completing comprehensive imaging examinations, molecular pathology tests, and overall functional assessments. Based on her previous treatment history, she was ultimately diagnosed with metastatic small cell neuroendocrine carcinoma (SCNEC) . SCNEC is a highly malignant neuroendocrine tumor with extremely aggressive activity. Ms. M had multiple metastases and was accompanied by typical symptoms of advanced cancer. She was physically weak and had very poor tolerance to traditional intravenous chemotherapy, putting her in a difficult situation for treatment. However, Ms. M's strong will to live moved the medical team. Based on her condition, physical condition and treatment needs, Harbor Health assisted in organizing multiple rounds of MDT consultations and assessments, and finally decided to perform transcatheter arterial infusion chemotherapy (TAI) combined with embolization therapy —that is, precision interventional chemotherapy.

Why China

Harbor Health connected the patient with appropriate Chinese medical resources, coordinated expert review, hospital access, interpretation, and treatment planning based on the case needs.

Treatment & Benefits

Precision interventional chemotherapy controlled advanced symptoms.

Full Story

Harbor Health quickly assisted Ms. M in completing comprehensive imaging examinations, molecular pathology tests, and overall functional assessments. Based on her previous treatment history, she was ultimately diagnosed with metastatic small cell neuroendocrine carcinoma (SCNEC) . SCNEC is a highly malignant neuroendocrine tumor with extremely aggressive activity. Ms. M had multiple metastases and was accompanied by typical symptoms of advanced cancer. She was physically weak and had very poor tolerance to traditional intravenous chemotherapy, putting her in a difficult situation for treatment.

However, Ms. M's strong will to live moved the medical team. Based on her condition, physical condition and treatment needs, Harbor Health assisted in organizing multiple rounds of MDT consultations and assessments, and finally decided to perform transcatheter arterial infusion chemotherapy (TAI) combined with embolization therapy —that is, precision interventional chemotherapy.

What is precision interventional chemotherapy? Its core is "targeted delivery and minimally invasive precision" . Relying on imaging equipment such as DSA (digital subtraction angiography) for real-time guidance, a microcatheter is percutaneously punctured and precisely inserted into the tumor's blood supply artery. Chemotherapy drugs are infused "point-to-point", and at the same time, the tumor's blood supply is blocked by embolization, thus doubly killing cancer cells.

Compared to traditional intravenous chemotherapy, precise interventional chemotherapy has prominent characteristics , which are also key to its suitability for Ms. M's condition: First, it has precise and potent local efficacy , with local drug concentrations reaching 50-100 times that of systemic chemotherapy, enabling precise killing of tumor cells and inhibition of lesion progression, with stronger targeting of multiple metastatic lesions; Second, it significantly reduces systemic toxicity and side effects , as the drug is mainly confined to the tumor site with extremely low blood doses, effectively avoiding common systemic adverse reactions of traditional chemotherapy such as nausea, vomiting, hair loss, and bone marrow suppression, greatly alleviating patient suffering; Third, it is minimally invasive, safe, and repeatable , requiring only a puncture incision the size of a grain of rice, without the need for abdominal surgery, resulting in rapid postoperative recovery. Treatment can be administered multiple times according to changes in the patient's condition and treatment response, continuously controlling the tumor; Fourth, it has broad indications and high tolerability , ensuring efficacy while maximizing the protection of normal bodily functions for late-stage patients who are weak and cannot tolerate systemic chemotherapy, achieving "treating tumors while preserving life."

After undergoing precise interventional chemotherapy according to a standardized treatment plan, Ms. M's condition was effectively controlled, and the symptoms caused by late-stage cancer, such as pain, fatigue, and loss of appetite, were significantly relieved, and her mental state improved greatly.

Meanwhile, Harbor Health emphasizes that precision interventional chemotherapy is not suitable for all cancer patients; its indications are clearly defined medically, and it is particularly effective for advanced malignant solid tumors. In terms of the types of cancer treated, it is mainly applicable to liver cancer, lung cancer, cervical cancer, endometrial cancer, bladder cancer, pancreatic cancer, biliary tract tumors, gastrointestinal tumors, and various malignant tumor metastases, including highly malignant tumors such as SCNEC.